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Hemofiltration treatment for sepsis: Is it time for controlled hemodynamics [1]. During septic shock in dogs, Freeman
trials? While the use of hemofiltration to treat septic shock has et al demonstrated that low-volume CAVH (60 ml/kg/
potential benefits, the existing studies are difficult to compare hr) failed to improve hemodynamics or the survival ratebecause of their variety of inclusion criteria. The concept is to
[2]. In a dog model of live Escherichia coli sepsis, Gomezremove the various mediators of severe sepsis and septic shock,
et al showed that low-volume (27 ml/kg/hr) CAVH in-such as cytokines and eicosanoids, so that acute renal failure
and the resultant multi-organ failure and possible death can be creased cardiac contractility [3], but the hemodynamic
delayed or prevented. The dilemmas include: (a) hemofiltration variables were not significantly compromised during
cannot distinguish between these pro-inflammatory mediators their study. In canine live E. coli sepsis, the same groupas they are of similar molecular weights, and thus it is difficult
of investigators recently reported that the combinationto determine which one or combination should be eliminated
of low-volume CAVH (16 ml/kg/hr) and phenylephrinefor the best hemodynamics; (b) timing of the hemofiltration
to remove a particular cytokine may make a difference in could restore stroke volume, suggesting that low-volume
patient outcome; (c) the most efficacious convection rate of CAVH alone may not be sufficient to improve hemody-
ultrafiltration has not been determined yet; (d) since these namics in these conditions [4]. However, in endotoxicmediators quickly saturate the membrane, it should be fre-
rats, Heidemann, Ofenstein, and Sarnaik were able toquently changed, and thus biocompatibility, availability and
improve short-term survival with CAVH (22 to 48 ml/costs are added issues; (e) the choice of buffer is different
according to the diagnosis of these critically ill patients. Before kg/hr) [5], and this was associated with the removal of
designing clinical trials, further experimentation is necessary thromboxane B2. In pigs with Staphylococcus aureus
to explore these problems. sepsis, Lee et al showed that CAVH (133 ml/kg/hr) did
not alter arterial blood pressure [6], but survival signifi-
cantly increased with hemofiltration. Grootendorst et al
Recently, hemofiltration has gained more importance studied the effect of high-volume continuous venovenous
as a possible treatment of severe sepsis and septic shock. hemofiltration (CVVH; 162 ml/kg/hr or 6 liters/hr) in
Indeed, during the past decade, various experimental pigs with endotoxic shock and found that CVVH was
studies have been performed in acute endotoxic or septic associated with greater arterial blood pressure and car-
shock in different animal models in vivo, focusing on diac output, as well as right ventricular ejection fraction
the hemodynamic response. At the same time, in vitro [7, 8]. In another model of gut ischemia and reperfusion
studies were done to examine the removal of different in pigs, the same authors reported that CVVH, started
cytokines, both by convection and adsorption. before clamping of the superior mesenteric artery, sig-
Clinical studies that looked at clinical outcome and nificantly increased arterial blood pressure, improved
removal of cytokines were done in patients with sepsis cardiac function, reduced macroscopic gut damage, and
and septic shock. improved 24-hour survival [9].
We studied the effects of CVVH with two different
ultrafiltrate rates (107 and 214 ml/kg/hr or 3 and 6 liters/EXPERIMENTAL STUDIES IN VIVO
hr, respectively) in a canine model of acute endotoxicDuring endotoxic shock in pigs, Stein et al showed
shock and were able to demonstrate positive hemody-that low-volume continuous arteriovenous hemofiltra-
namic effects in the high-volume group [10]. In a studytion (CAVH; 20 ml/kg/hr) did not significantly influence
using again low-volume hemofiltration (33 ml/kg/hr),
Murphey et al were not able to demonstrate any cardio-
pulmonary improvement in a porcine model of acuteKey words: hemodynamics, acute endotoxic shock, cytokines, continu-
ous arteriovenous hemofiltration, biocompatible membranes. endotoxin shock [11]. Two experimental studies were
recently performed using high-pore membranes, which 1999 by the International Society of Nephrology
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increased the cut-off point of the membrane from ap- Clinical studies
proximately 40 kDa to approximately 80 kDa, and re- Elliott, Wiles, and Reynolds could detect consider-
sulted in hemodynamic improvement and an increase in able amounts of TNF and IL-1 in the ultrafiltrate of pa-
the survival rate [12, 13]. tients treated with continuous arteriovenous hemodialy-
sis (CAVHD) or continuous venovenous hemodialysis
(CVVHD) [24]. Despite the removal of considerableREMOVAL OF MEDIATORS OF SEPSIS
amounts of TNF with CVVH in patients with multiple
A number of mediators such as eicosanoids, cytokines organ failure, Kierdorf et al found no reduction in plasma
[tumor necrosis factor (TNF), interleukins (IL)-1, -6, -8], TNF levels (abstract; Kierdorf et al, Ren Fail 14:98, 1992).
endothelin, and platelet-activating factor (PAF) are in- Millar et al found a reduction in serum TNF, but not in
volved in the development of septic shock. Is there exper- IL-6 or IL-8 plasma levels in children with multiple organ
imental or clinical evidence that hemofiltration can re- failure treated with hemofiltration [25]. Andreasson et
move these mediators? al [18] and Journois [26] found that hemofiltration can
reduce complement levels after cardiopulmonary bypass.
Experimental studies In patients with sepsis and acute renal failure, Bellomo,
Because of their biocompatibility and their high per- Tipping, and Boyce could detect considerable amounts
meability, synthetic membranes are widely used for he- of IL-6 and IL-8 in the ultrafiltrate [27]. In patients with
mofiltration, allowing convective removal of small mole- acute renal failure and sepsis, van Bommel et al found
cules such as urea and creatinine, and also ions. These that TNF can be removed from the circulation mainly
membranes have a sieving coefficient of 0.55 for myoglo- by adsorption and that IL-1 and IL-6 are removed by
bin, in which the molecular weight is 17,000 Da, that is, convection [28]. In septic patients treated with CVVH,
very close to that of TNF-a (16,500 Da). By using these Hoffmann et al could not demonstrate significant re-
membranes, the TNF-a monomer and various cytokines moval of TNF, IL-1, IL-6, or IL-8, but complement levels
could be significantly lowered [29, 30]. Incubation ofthat are responsible for myocardial dysfunction can theo-
lymphocytes with ultrafiltrate from these septic patientsretically be removed by convection. The biological form
stimulated TNF release and suppressed IL-2 and IL-6of TNF, however, is a trimer that has a molecular weight
release. Tonnesen et al found significant removal of TNFthat is too big to pass hemofiltration membranes. Lonne-
and IL-6 in septic patients treated with CAVH [31].man et al showed significant removal of TNF and IL-1,
Despite considerable amounts of TNF and IL-6 in theusing AN69 and polysulfone membranes in an in vitro
ultrafiltrate of septic patients, Sander et al did not finddialysis system [14]. These data were confirmed by others
a decrease in plasma cytokine levels [32]. CVVH with[15–18]. In vitro, hemofiltration of a 1% albumin solution
PAN filters decreased factor D levels, resulting in re-containing TNF and IL-1 through a variety of filters
duced complement activation in critically ill patients withresulted in higher sieving coefficients of the two cyto-
acute renal failure [33]. In a recent study performed bykines than expected. This was because of a 32% binding
Kellum et al, CVVH resulted in decreased plasma TNFeffect by the membranes [16]. Because of its high molecu-
levels while levels of IL-6, IL-8, soluble l-selectin, andlar weight, endotoxin cannot be readily removed from
endotoxin remained unchanged [34].the circulation, but endotoxin fragments can be elimi-
nated. An interesting technique is the specific adsorption
of endotoxin with polymyxin using different systems of CLINICAL STUDIES IN CRITICALLY ILL
hemofiltration [19, 20]. In vivo, Sato, Orlowski, and PATIENTS WITH SEPSIS
Zborowski showed that hemoperfusion using a poly- Very few of these studies were obtained prospectively;
myxin B fiber column can decrease circulating endotoxin historical controls were used in most cases. Different
and TNF levels in live E. coli shock in dogs [21]. hemofilters and volumes were used, making a compari-
Obviously, the potential benefits related to hemofil- son between these studies very difficult. Another draw-
tration are not restricted to the elimination of cytokines. back was the limited number of patients, making statisti-
Complement factors (molecular weight 10,000 to 12,000), cal analysis difficult to interpret. Moreover, because most
b-endorphin (molecular weight 4000), bradykinin (mo- of the studies were performed in patients with already
lecular weight 1060), or arachidonic acid metabolites established acute renal failure, the positive effects could
(molecular weight 600) can also be removed from circu- be the result of a better metabolic and fluid balance
lation. In particular, arachidonic acid metabolites, in- control.
cluding prostacyclin, thromboxane, and leukotrienes, In an uncontrolled study, Gotloib et al showed a sur-
have been shown to be removed by hemofiltration in prisingly high survival rate of 92% in acute respiratory
animals and patients [22, 23], and this has been suggested distress syndrome (ARDS) patients treated with inter-
mittent hemofiltration [22]. Coraim et al applied CAVHto be related to some hemodynamic improvement.
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in 36 patients suffering from “postperfusion syndrome” cal trials, many problems and questions need to be ad-
dressed. More experimental work should be performedafter cardiac surgery, which was characterized by acute
respiratory failure, arterial hypotension, low systemic about kinetics of various mediators in severe sepsis and
septic shock. It is now known that in severe sepsis, bothvascular resistance, and high lactate levels [35]. CAVH
treatment improved oxygenation and oxygen delivery, proinflammatory and anti-inflammatory mediators are
excessively released by a number of cells, leading toresulting in a decreased mortality rate associated with
the removal of myocardial depressing substances. In a organ dysfunction and possibly death. Hemofiltration
cannot distinguish between these mediators, and there-retrospective analysis, Barzilay et al showed a decrease
in mortality rate in patients with multiple organ failure fore, the simultaneous removal of a particular cytokine
and its inhibitor may influence the resulting cytokinetreated with either CAVH or plasmapheresis [36]. The
study population was separated into four different sub- bioactivity [46].
A difficult question is the timing of hemofiltration. Ifgroups so that the number of patients in each subgroup
was too small for adequate statistical interpretation. In hemofiltration can be beneficial in patients with severe
sepsis or septic shock, by eliminating proinflammatorya retrospective and uncontrolled analysis, both Bagshaw,
Anaes, and Hutchinson and DiCarlo et al found an im- cytokines, it may be necessary to initiate it as soon as
possible, even before the development of acute renalproved respiratory function in patients with multiple or-
gan failure treated with CAVH [37, 38]. Boulain et al failure, to prevent organ dysfunction caused by irrevers-
ible changes in the late stage of sepsis.demonstrated a greater hemodynamic stability, a higher
nitrogen supply, and a lower mortality rate with CVVH Another important question is the ultrafiltration rate
to be applied. Because mediators are mainly removedcompared with sequential hemodialysis in 18 patients
with acute renal failure and multiple organ failure [39]. from the circulation by convection, this removal is di-
rectly related to the amount of ultrafiltration. This ex-Riegel et al observed an attenuation of the elevated
cardiac output, less decrease of systemic vascular resis- plains the differences between low- and high-volume
hemofiltration in the experimental literature. High vol-tance, and an enhanced oxygen extraction ratio in pa-
umes are probably required, but whether levels as hightients with systemic inflammatory response syndrome
as 6 liters/hr are necessary needs further investigation.(SIRS) who were treated with CVVH compared with a
Another approach could be to increase the membranecontrol group [40]. A similar increase in systemic vascu-
permeability. By increasing filter pore size, the cut-offlar resistance was found in Sander et al’s study after 48
point of the membrane could be increased from abouthours of isovolemic CVVH in patents with septic shock
40 kDa up to 80 kDa, making the removal of molecules[32]. Braun et al observed a significant decline in the
such as the TNF-trimer possible.APACHE III score of patients with SIRS treated with
Because adsorption of cytokines by the membraneCVVH (abstract; Braun et al, J Am Soc Nephrol 4:A336,
probably also plays a role, different membranes should1993) [41]. Bellomo et al reported a better control of
be compared in terms of efficacy, cost, and side effects.uremia and acidosis and even an improved survival with
Frequent changing of the membrane may be desirableCVVHD compared with conventional hemodialysis in
to avoid saturation and desorption of cytokines.87 patients with sepsis-associated acute renal failure [42].
The choice of buffer could also play a role: In hemody-Similar results were reported by van Bommel et al in 60
namically unstable patients with lactic acidosis, a bicar-high-risk surgical patients with acute renal failure [43].
bonate buffer should be preferred to a lactate or acetateIn a retrospective, uncontrolled study, Gotloib et al also
buffer.showed a decreased mortality rate in patients with multi-
Meanwhile, we should join and discuss the design ofple organ failure treated with sequential hemofiltration
future clinical trials. It is only by means of properlyas compared with conventional treatment [44]. Recently,
designed, prospective, randomized, multicenter clinicalBellomo et al compared high-volume hemofiltration to
trials that the evidence on whether or not hemofiltrationconventional hemofiltration in human septic shock and
has a role in the treatment of severe sepsis can be proven.found a significant reduction of vasopressor requirement
in the high-volume group [45]. Reprint requests to Peter Rogiers, M.D., Department of Intensive
Care, Middelheim General Hospital, Lindendreef 1, B-2020 Antwerpen,
Belgium.
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